EMA Recommends Change in Storage Conditions for Pfizer/BioNTech Vaccine
The agency’s human medicines committee has recommended extending the approved storage period of unopened thawed vials at 2–8 0C from five days to 31 days.
The European Medicines Agency (EMA) announced on May 17, 2021 that its human medicines committee (CHMP) has recommended changing the approved storage conditions for Pfizer/BioNTech’s COVID-19 vaccine, Comirnaty. The recommendation extends the approved storage period of the unopened thawed vial at 2–8 oC from five days to 31 days.
The change follows EMA’s assessment of additional stability data, and the agency expects it to have an impact on planning and logistics for the rollout of the vaccine to member states in the European Union. The change will be implemented in updated product labeling.
Source: EMA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
